SummaryIntroduction: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This is easily demonstrated if dilation is tested following methacholine challenge. It is not known how quickly tolerance develops or how long it lasts after stopping beta-agonist therapy.Methods: Ten subjects with stable asthma were studied. Following 2 weeks without beta-agonists, methacholine was inhaled to induce a 20% reduction in FEV1. The response to inhaled salbutamol (100, 100, 200μg at 5-min intervals) was then measured. This procedure was repeated 24h after one dose and 24h after 3, 7 and 14 days of inhaled formoterol 12μg twice daily, and 3 and 5 days after formoterol was discontinued. Unscheduled use of beta-agonists was not pe...
It has been suggested that regular treatment with high doses of beta 2-agonists might result in poor...
The mechanisms underlying bronchial hyperreactivity, a characteristic feature of asthma, and the mec...
Regular use of beta2-agonists might result in increased bronchial hyper-responsiveness (BHR) and dec...
SummaryIntroduction: Regular use of beta-agonists leads to tolerance to their bronchodilator effects...
Abstract Background Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator ...
ABSTRACT: Continuous treatment with a short-acting b2-agonist can lead to reduced bronchodilator res...
ABSTRACT: Chronic exposure to b-agonists causes tolerance to their bronchodilator effects, which is ...
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of b...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
BACKGROUND AND OBJECTIVE: Long-acting beta(2)-agonists have acquired an indispensable position in th...
AbstractVirtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid on...
Fenoterol with ipratropium bromide (Duovent) is a recently used combination between an anticholinerg...
AbstractLoss of bronchodilator effectiveness or tolerance has been observed with inhaled beta-agonis...
In vitro data suggest that salmeterol, contrary to formoterol, can partly antagonise the effect of s...
AbstractThis single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 m...
It has been suggested that regular treatment with high doses of beta 2-agonists might result in poor...
The mechanisms underlying bronchial hyperreactivity, a characteristic feature of asthma, and the mec...
Regular use of beta2-agonists might result in increased bronchial hyper-responsiveness (BHR) and dec...
SummaryIntroduction: Regular use of beta-agonists leads to tolerance to their bronchodilator effects...
Abstract Background Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator ...
ABSTRACT: Continuous treatment with a short-acting b2-agonist can lead to reduced bronchodilator res...
ABSTRACT: Chronic exposure to b-agonists causes tolerance to their bronchodilator effects, which is ...
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of b...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
BACKGROUND AND OBJECTIVE: Long-acting beta(2)-agonists have acquired an indispensable position in th...
AbstractVirtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid on...
Fenoterol with ipratropium bromide (Duovent) is a recently used combination between an anticholinerg...
AbstractLoss of bronchodilator effectiveness or tolerance has been observed with inhaled beta-agonis...
In vitro data suggest that salmeterol, contrary to formoterol, can partly antagonise the effect of s...
AbstractThis single-centre, randomized, double-blind, double-dummy four-way cross-over study in 24 m...
It has been suggested that regular treatment with high doses of beta 2-agonists might result in poor...
The mechanisms underlying bronchial hyperreactivity, a characteristic feature of asthma, and the mec...
Regular use of beta2-agonists might result in increased bronchial hyper-responsiveness (BHR) and dec...